

## Supporting Information

# Antimicrobial activity of linear lipopeptides derived from BP100 towards plant pathogens

Àngel Oliveras, Aina Baró, Laura Montesinos, Esther Badosa, Emilio Montesinos, Lidia Feliu\*,  
and Marta Planas\*

### Table of contents:

1. Antimicrobial and hemolytic activity of lipopeptides <b>BP367-BP402</b> .....	2
2. Synthesis of lipopeptides <b>BP367-BP402</b> .....	5
3. Characterization of lipopeptides <b>BP367-BP402</b> : HPLC of crude and purified lipopeptides, ESI-MS and HRMS .....	16

# 1. Antimicrobial and hemolytic activity of lipopeptides BP367-BP402

**Table A.** Antimicrobial activity (MIC) of the linear lipopeptides against six plant pathogenic bacteria and two fungi

Peptide	Structure <sup>a</sup>	<i>Ea</i> <sup>b</sup>	<i>Pss</i> <sup>b</sup>	<i>Psa</i> <sup>b</sup>	<i>Xap</i> <sup>b</sup>	<i>Xf</i> <sup>b</sup>	<i>Xav</i> <sup>b</sup>	<i>Pe</i> <sup>b</sup>	<i>Fo</i> <sup>b</sup>
<b>BP100</b>	KKLFKKILKYL-NH <sub>2</sub>	3.1-6.2	3.1-6.2	1.6-3.1	1.6-3.1	3.1-6.2	3.1-6.2	>25	0.8-1.6
<b>BP367</b>	C <sub>5</sub> H <sub>11</sub> CO-KKLFKKILKYL-NH <sub>2</sub>	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	12.5-25	1.6-3.1
<b>BP368</b>	Ac-K(COC <sub>5</sub> H <sub>11</sub> )KLFKKILKYL-NH <sub>2</sub>	6.2-12.5	6.2-12.5	6.2-12.5	3.1-6.2	6.2-12.5	3.1-6.2	1.6-3.1	0.8-1.6
<b>BP369</b>	Ac-KK(COC <sub>5</sub> H <sub>11</sub> )LFKKILKYL-NH <sub>2</sub>	6.2-12.5	6.2-12.5	3.1-6.2	0.8-1.6	3.1-6.2	3.1-6.2	1.6-3.1	0.4-0.8
<b>BP370</b>	Ac-KKK(COC <sub>5</sub> H <sub>11</sub> )FKKILKYL-NH <sub>2</sub>	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	6.2-12.5	3.1-6.2	6.2-12.5	0.8-1.6
<b>BP371</b>	Ac-KKLC(COC <sub>5</sub> H <sub>11</sub> )KKILKYL-NH <sub>2</sub>	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	0.8-1.6
<b>BP372</b>	Ac-KKLFK(COC <sub>5</sub> H <sub>11</sub> )KILKYL-NH <sub>2</sub>	6.2-12.5	6.2-12.5	6.2-12.5	3.1-6.2	3.1-6.2	6.2-12.5	6.2-12.5	0.8-1.6
<b>BP373</b>	Ac-KKLFKK(COC <sub>5</sub> H <sub>11</sub> )ILKYL-NH <sub>2</sub>	3.1-6.2	6.2-12.5	3.1-6.2	3.1-6.2	3.1-6.2	6.2-12.5	3.1-6.2	0.4-0.8
<b>BP374</b>	Ac-KKLFKKK(COC <sub>5</sub> H <sub>11</sub> )LKYL-NH <sub>2</sub>	3.1-6.2	6.2-12.5	3.1-6.2	6.2-12.5	3.1-6.2	6.2-12.5	>25	0.8-1.6
<b>BP375</b>	Ac-KKLFKKIK(COC <sub>5</sub> H <sub>11</sub> )KYL-NH <sub>2</sub>	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	6.2-12.5	3.1-6.2	0.4-0.8
<b>BP376</b>	Ac-KKLFKKILK(COC <sub>5</sub> H <sub>11</sub> )YL-NH <sub>2</sub>	6.2-12.5	12.5-25	3.1-6.2	6.2-12.5	3.1-6.2	6.2-12.5	3.1-6.2	0.4-0.8
<b>BP377</b>	Ac-KKLFKKILKK(COC <sub>5</sub> H <sub>11</sub> )L-NH <sub>2</sub>	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	6.2-12.5	3.1-6.2	0.8-1.6
<b>BP378</b>	Ac-KKLFKKILKYK(COC <sub>5</sub> H <sub>11</sub> )-NH <sub>2</sub>	3.1-6.2	6.2-12.5	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	0.8-1.6
<b>BP379</b>	C <sub>3</sub> H <sub>7</sub> CO-KKLFKKILKYL-NH <sub>2</sub>	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	6.2-12.5	3.1-6.2
<b>BP380</b>	Ac-K(COC <sub>3</sub> H <sub>7</sub> )KLFKKILKYL-NH <sub>2</sub>	3.1-6.2	6.2-12.5	6.2-12.5	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	0.8-1.6
<b>BP381</b>	Ac-KK(COC <sub>3</sub> H <sub>7</sub> )LFKKILKYL-NH <sub>2</sub>	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	1.6-3.1	1.6-3.1	1.6-3.1	0.8-1.6
<b>BP382</b>	Ac-KKK(COC <sub>3</sub> H <sub>7</sub> )FKKILKYL-NH <sub>2</sub>	6.2-12.5	6.2-12.5	6.2-12.5	6.2-12.5	1.6-3.1	6.2-12.5	3.1-6.2	0.8-1.6
<b>BP383</b>	Ac-KKLC(COC <sub>3</sub> H <sub>7</sub> )KKILKYL-NH <sub>2</sub>	6.2-12.5	6.2-12.5	6.2-12.5	6.2-12.5	3.1-6.2	3.1-6.2	6.2-12.5	0.8-1.6
<b>BP384</b>	Ac-KKLFK(COC <sub>3</sub> H <sub>7</sub> )KILKYL-NH <sub>2</sub>	3.1-6.2	6.2-12.5	6.2-12.5	3.1-6.2	1.6-3.1	1.6-3.1	12.5-25	1.6-3.1
<b>BP385</b>	Ac-KKLFKK(COC <sub>3</sub> H <sub>7</sub> )ILKYL-NH <sub>2</sub>	6.2-12.5	6.2-12.5	6.2-12.5	0.8-1.6	1.6-3.1	0.8-1.6	6.2-12.5	1.6-3.1
<b>BP386</b>	Ac-KKLFKKK(COC <sub>3</sub> H <sub>7</sub> )LKYL-NH <sub>2</sub>	12.5-25	6.5-12.5	6.2-12.5	12.5-25	12.5-25	12.5-25	>25	12.5-25
<b>BP387</b>	Ac-KKLFKKIK(COC <sub>3</sub> H <sub>7</sub> )KYL-NH <sub>2</sub>	3.1-6.2	3.1-6.2	3.1-6.2	3.1-6.2	1.6-3.1	1.6-3.1	6.2-12.5	0.8-1.6
<b>BP388</b>	Ac-KKLFKKILK(COC <sub>3</sub> H <sub>7</sub> )YL-NH <sub>2</sub>	3.1-6.2	6.2-12.5	6.2-12.5	3.1-6.2	1.6-3.1	1.6-3.1	6.2-12.5	0.8-1.6
<b>BP389</b>	Ac-KKLFKKILKK(COC <sub>3</sub> H <sub>7</sub> )L-NH <sub>2</sub>	3.1-6.2	6.2-12.5	3.1-6.2	0.8-1.6	1.6-3.1	0.8-1.6	6.2-12.5	1.6-3.1
<b>BP390</b>	Ac-KKLFKKILKYK(COC <sub>3</sub> H <sub>7</sub> )-NH <sub>2</sub>	3.1-6.2	6.2-12.5	6.2-12.5	6.2-12.5	3.1-6.2	3.1-6.2	6.2-12.5	0.8-1.6

<b>BP391</b>	C <sub>11</sub> H <sub>23</sub> CO-KKLFKKILKYL-NH <sub>2</sub>	>25	>25	>25	6.2-12.5	3.1-6.2	6.2-12.5	>25	12.5-25
<b>BP392</b>	Ac-K(COC <sub>11</sub> H <sub>23</sub> )KLFKKILKYL-NH <sub>2</sub>	>25	>25	>25	3.1-6.2	0.8-1.6	3.1-6.2	>25	6.2-12.5
<b>BP393</b>	Ac-KK(COC <sub>11</sub> H <sub>23</sub> )LFKKILKYL-NH <sub>2</sub>	12.5-25	12.5-25	6.2-12.5	3.1-6.2	3.1-6.2	3.1-6.2	>25	1.6-3.1
<b>BP394</b>	Ac-KKK(COC <sub>11</sub> H <sub>23</sub> )FKKILKYL-NH <sub>2</sub>	12.5 -25	6.2-12.5	6.2-12.5	1.6-3.1	0.8-1.6	1.6-3.1	12.5-25	6.2-12.5
<b>BP395</b>	Ac-KKLK(COC <sub>11</sub> H <sub>23</sub> )KKILKYL-NH <sub>2</sub>	12.5 -25	3.1-6.2	3.1-6.2	1.6-3.1	1.6-3.1	1.6-3.1	12.5-25	6.2-12.5
<b>BP396</b>	Ac-KKLFK(COC <sub>11</sub> H <sub>23</sub> )KILKYL-NH <sub>2</sub>	>25	>25	>25	1.6-3.1	1.6-3.1	3.1-6.2	12.5-25	6.2-12.5
<b>BP397</b>	Ac-KKLFKK(COC <sub>11</sub> H <sub>23</sub> )ILKYL-NH <sub>2</sub>	>25	>25	>25	3.1-6.2	1.6-3.1	6.2-12.5	12.5-25	6.2-12.5
<b>BP398</b>	Ac-KKLFKKK(COC <sub>11</sub> H <sub>23</sub> )LKYL-NH <sub>2</sub>	>25	3.1-6.2	3.1-6.2	1.6-3.1	3.1-6.2	0.8-1.6	>25	6.2-12.5
<b>BP399</b>	Ac-KKLFKKIK(COC <sub>11</sub> H <sub>23</sub> )KYL-NH <sub>2</sub>	>25	3.1-6.2	3.1-6.2	1.6-3.1	3.1-6.2	0.8-1.6	12.5-25	6.2-12.5
<b>BP400</b>	Ac-KKLFKKILK(COC <sub>11</sub> H <sub>23</sub> )YL-NH <sub>2</sub>	>25	>25	>25	1.6-3.1	3.1-6.2	1.6-3.1	>25	6.2-12.5
<b>BP401</b>	Ac-KKLFKKILKK(COC <sub>11</sub> H <sub>23</sub> )L-NH <sub>2</sub>	>25	6.2-12.5	6.2-12.5	1.6-3.1	3.1-6.2	0.8-1.6	12.5-25	6.2-12.5
<b>BP402</b>	Ac-KKLFKKILKYK(COC <sub>11</sub> H <sub>23</sub> )-NH <sub>2</sub>	3.1-6.2	3.1-6.2	3.1-6.2	1.6-3.1	3.1-6.2	1.6-3.1	12.5-25	6.2-12.5

<sup>a</sup>COC<sub>5</sub>H<sub>11</sub>, hexanoyl; COC<sub>3</sub>H<sub>7</sub>, butanoyl; COC<sub>11</sub>H<sub>23</sub>, lauroyl.

<sup>b</sup>*Ea*, *Erwinia amylovora*; *Pss*, *Pseudomonas syringae* pv. *syringae*; *Psa*, *Pseudomonas syringae* pv. *actinidiae*; *Xap*, *Xanthomonas arboricola* pv. *pruni*; *Xf*, *Xanthomonas fragariae*; *Xav*, *Xanthomonas axonopodis* pv. *vesicatoria*; *Pe*, *Penicillium expansum*; *Fo*, *Fusarium oxysporum*.

**Table B.** Hemolytic activity of the linear lipopeptides

Peptide	Structure <sup>a</sup>	250 $\mu$ M	375 $\mu$ M
<b>BP100</b>	KKLFKKILKYL-NH <sub>2</sub>	43 $\pm$ 1.4	57 $\pm$ 4.6
<b>BP367</b>	C <sub>5</sub> H <sub>11</sub> CO-KKLFKKILKYL-NH <sub>2</sub>	83 $\pm$ 6	95 $\pm$ 13
<b>BP368</b>	Ac-K(COC <sub>5</sub> H <sub>11</sub> )KLFKKILKYL-NH <sub>2</sub>	96 $\pm$ 0.9	97 $\pm$ 3
<b>BP369</b>	Ac-KK(COC <sub>5</sub> H <sub>11</sub> )LFKKILKYL-NH <sub>2</sub>	84 $\pm$ 8	86 $\pm$ 8
<b>BP370</b>	Ac-KKK(COC <sub>5</sub> H <sub>11</sub> )FKKILKYL-NH <sub>2</sub>	11 $\pm$ 2	14 $\pm$ 3
<b>BP371</b>	Ac-KKLK(COC <sub>5</sub> H <sub>11</sub> )KKILKYL-NH <sub>2</sub>	75 $\pm$ 4	95 $\pm$ 3
<b>BP372</b>	Ac-KKLFK(COC <sub>5</sub> H <sub>11</sub> )KILKYL-NH <sub>2</sub>	97 $\pm$ 2	100 $\pm$ 0.9
<b>BP373</b>	Ac-KKLFKK(COC <sub>5</sub> H <sub>11</sub> )ILKYL-NH <sub>2</sub>	92 $\pm$ 1	95 $\pm$ 6
<b>BP374</b>	Ac-KKLFKKK(COC <sub>5</sub> H <sub>11</sub> )LKYL-NH <sub>2</sub>	19 $\pm$ 3	28 $\pm$ 2
<b>BP375</b>	Ac-KKLFKKIK(COC <sub>5</sub> H <sub>11</sub> )KYL-NH <sub>2</sub>	70 $\pm$ 6	86 $\pm$ 3
<b>BP376</b>	Ac-KKLFKKILK(COC <sub>5</sub> H <sub>11</sub> )YL-NH <sub>2</sub>	90 $\pm$ 4	89 $\pm$ 2
<b>BP377</b>	Ac-KKLFKKILKK(COC <sub>5</sub> H <sub>11</sub> )L-NH <sub>2</sub>	92 $\pm$ 5	89 $\pm$ 2
<b>BP378</b>	Ac-KKLFKKILKYK(COC <sub>5</sub> H <sub>11</sub> )-NH <sub>2</sub>	26 $\pm$ 0.4	52 $\pm$ 6
<b>BP379</b>	C <sub>3</sub> H <sub>7</sub> CO-KKLFKKILKYL-NH <sub>2</sub>	93 $\pm$ 0.8	96 $\pm$ 1
<b>BP380</b>	Ac-K(COC <sub>3</sub> H <sub>7</sub> )KLFKKILKYL-NH <sub>2</sub>	93 $\pm$ 6	97 $\pm$ 5
<b>BP381</b>	Ac-KK(COC <sub>3</sub> H <sub>7</sub> )LFKKILKYL-NH <sub>2</sub>	54 $\pm$ 6	76 $\pm$ 2
<b>BP382</b>	Ac-KKK(COC <sub>3</sub> H <sub>7</sub> )FKKILKYL-NH <sub>2</sub>	100 $\pm$ 0.9	100 $\pm$ 2
<b>BP383</b>	Ac-KKLK(COC <sub>3</sub> H <sub>7</sub> )KKILKYL-NH <sub>2</sub>	22 $\pm$ 4	40 $\pm$ 4
<b>BP384</b>	Ac-KKLFK(COC <sub>3</sub> H <sub>7</sub> )KILKYL-NH <sub>2</sub>	100 $\pm$ 4	100 $\pm$ 2
<b>BP385</b>	Ac-KKLFKK(COC <sub>3</sub> H <sub>7</sub> )ILKYL-NH <sub>2</sub>	100 $\pm$ 3	100 $\pm$ 4
<b>BP386</b>	Ac-KKLFKKK(COC <sub>3</sub> H <sub>7</sub> )LKYL-NH <sub>2</sub>	1 $\pm$ 0.1	3 $\pm$ 0
<b>BP387</b>	Ac-KKLFKKIK(COC <sub>3</sub> H <sub>7</sub> )KYL-NH <sub>2</sub>	14 $\pm$ 0.5	18 $\pm$ 1
<b>BP388</b>	Ac-KKLFKKILK(COC <sub>3</sub> H <sub>7</sub> )YL-NH <sub>2</sub>	38 $\pm$ 4	89 $\pm$ 10
<b>BP389</b>	Ac-KKLFKKILKK(COC <sub>3</sub> H <sub>7</sub> )L-NH <sub>2</sub>	22 $\pm$ 2	39 $\pm$ 3
<b>BP390</b>	Ac-KKLFKKILKYK(COC <sub>3</sub> H <sub>7</sub> )-NH <sub>2</sub>	5 $\pm$ 0.3	7 $\pm$ 0.9
<b>BP391</b>	C <sub>11</sub> H <sub>23</sub> CO-KKLFKKILKYL-NH <sub>2</sub>	100 $\pm$ 0.9	100 $\pm$ 0.5
<b>BP392</b>	Ac-K(COC <sub>11</sub> H <sub>23</sub> )KLFKKILKYL-NH <sub>2</sub>	100 $\pm$ 0.9	100 $\pm$ 2
<b>BP393</b>	Ac-KK(COC <sub>11</sub> H <sub>23</sub> )LFKKILKYL-NH <sub>2</sub>	97 $\pm$ 0.6	99 $\pm$ 0.5
<b>BP394</b>	Ac-KKK(COC <sub>11</sub> H <sub>23</sub> )FKKILKYL-NH <sub>2</sub>	100 $\pm$ 1	100 $\pm$ 2
<b>BP395</b>	Ac-KKLK(COC <sub>11</sub> H <sub>23</sub> )KKILKYL-NH <sub>2</sub>	100 $\pm$ 2	100 $\pm$ 2
<b>BP396</b>	Ac-KKLFK(COC <sub>11</sub> H <sub>23</sub> )KILKYL-NH <sub>2</sub>	100 $\pm$ 4	100 $\pm$ 7
<b>BP397</b>	Ac-KKLFKK(COC <sub>11</sub> H <sub>23</sub> )ILKYL-NH <sub>2</sub>	100 $\pm$ 4	100 $\pm$ 5
<b>BP398</b>	Ac-KKLFKKK(COC <sub>11</sub> H <sub>23</sub> )LKYL-NH <sub>2</sub>	100 $\pm$ 3	100 $\pm$ 5
<b>BP399</b>	Ac-KKLFKKIK(COC <sub>11</sub> H <sub>23</sub> )KYL-NH <sub>2</sub>	100 $\pm$ 5	100 $\pm$ 6
<b>BP400</b>	Ac-KKLFKKILK(COC <sub>11</sub> H <sub>23</sub> )YL-NH <sub>2</sub>	99 $\pm$ 0.4	100 $\pm$ 14
<b>BP401</b>	Ac-KKLFKKILKK(COC <sub>11</sub> H <sub>23</sub> )L-NH <sub>2</sub>	100 $\pm$ 1	100 $\pm$ 3
<b>BP402</b>	Ac-KKLFKKILKYK(COC <sub>11</sub> H <sub>23</sub> )-NH <sub>2</sub>	100 $\pm$ 4	100 $\pm$ 0.5

<sup>a</sup>COC<sub>5</sub>H<sub>11</sub>, hexanoyl; COC<sub>3</sub>H<sub>7</sub>, butanoyl; COC<sub>11</sub>H<sub>23</sub>, lauroyl.

<sup>b</sup>Percent hemolysis at 250 and 375  $\mu$ M plus confidence interval ( $\alpha = 0.05$ )

## 2. Synthesis of lipopeptides BP367-BP402

### **C<sub>5</sub>H<sub>11</sub>CO-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP367)**

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (70:30) afforded C<sub>5</sub>H<sub>11</sub>CO-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP367**) in >99% purity.  $t_R = 7.77$  min. MS (ESI)  $m/z$ : 760.1 [M + 2H]<sup>2+</sup>, 1520.1 [M + H]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for C<sub>78</sub>H<sub>137</sub>N<sub>17</sub>O<sub>13</sub> [M + 2H]<sup>2+</sup> 760.0285, found 760.0270; calcd for C<sub>78</sub>H<sub>138</sub>N<sub>17</sub>O<sub>13</sub> [M + 3H]<sup>3+</sup> 507.0215, found 507.0201; calcd for C<sub>78</sub>H<sub>139</sub>N<sub>17</sub>O<sub>13</sub> [M + 4H]<sup>4+</sup> 380.5179, found 380.5165.

### **Ac-Lys(COC<sub>5</sub>H<sub>11</sub>)-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP368)**

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (70:30) afforded Ac-Lys(COC<sub>5</sub>H<sub>11</sub>)-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP368**) in >99% purity.  $t_R = 7.91$  min. MS (ESI)  $m/z$ : 521.3 [M + 3H]<sup>3+</sup>, 781.6 [M + 2H]<sup>2+</sup>, 1562.1 [M + H]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for C<sub>80</sub>H<sub>139</sub>N<sub>17</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 781.0338, found 781.0319; calcd for C<sub>80</sub>H<sub>140</sub>N<sub>17</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 521.0250, found 521.0252.

### **Ac-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP369)**

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded Ac-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP369**) in 92% purity.  $t_R = 7.53$  min. MS (ESI)  $m/z$ : 521.4 [M + 3H]<sup>3+</sup>, 781.1 [M + 2H]<sup>2+</sup>, 1562.1 [M + H]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for C<sub>80</sub>H<sub>139</sub>N<sub>17</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 781.0338, found 781.0316; calcd for C<sub>80</sub>H<sub>140</sub>N<sub>17</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 521.0250, found 521.0263; calcd for C<sub>80</sub>H<sub>141</sub>N<sub>17</sub>O<sub>14</sub> [M + 4H]<sup>4+</sup> 391.0205, found 391.0192.

### **Ac-Lys-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP370)**

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (80:20) afforded Ac-Lys-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP370**) in >99% purity. *t<sub>R</sub>* = 7.06 min. MS (ESI) *m/z*: 526.1 [M + 3H]<sup>3+</sup>, 789.1 [M + 2H]<sup>2+</sup>, 1577.1 [M + H]<sup>+</sup>; HRMS (ESI) *m/z*: calcd for C<sub>80</sub>H<sub>140</sub>N<sub>18</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 788.5393, found 788.5380; calcd for C<sub>80</sub>H<sub>141</sub>N<sub>18</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 526.0286, found 526.0275; calcd for C<sub>80</sub>H<sub>142</sub>N<sub>18</sub>O<sub>14</sub> [M + 4H]<sup>4+</sup> 394.7733, found 394.7725.

### **Ac-Lys-Lys-Leu-Lys(COC<sub>5</sub>H<sub>11</sub>)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP371)**

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (80:20) afforded Ac-Lys-Lys-Leu-Lys(COC<sub>5</sub>H<sub>11</sub>)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP371**) in >99% purity. *t<sub>R</sub>* = 7.11 min. MS (ESI) *m/z*: 771.6 [M + 2H]<sup>2+</sup>, 1542.2 [M + H]<sup>+</sup>; HRMS (ESI) *m/z*: calcd for C<sub>77</sub>H<sub>142</sub>N<sub>18</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 771.5471, found 771.5471; calcd for C<sub>77</sub>H<sub>143</sub>N<sub>18</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 514.7005, found 514.7003; calcd for C<sub>77</sub>H<sub>144</sub>N<sub>18</sub>O<sub>14</sub> [M + 4H]<sup>4+</sup> 386.2772, found 386.2768.

### **Ac-Lys-Lys-Leu-Phe-Lys(COC<sub>5</sub>H<sub>11</sub>)-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP372)**

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (70:30) afforded Ac-Lys-Lys-Leu-Phe-Lys(COC<sub>5</sub>H<sub>11</sub>)-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP372**) in >99% purity. *t<sub>R</sub>* = 7.64 min. MS (ESI) *m/z*: 781.1 [M + 2H]<sup>2+</sup>, 1562.1 [M + H]<sup>+</sup>; HRMS (ESI) *m/z*: calcd for C<sub>80</sub>H<sub>139</sub>N<sub>17</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 781.0338, found 781.0336; calcd for C<sub>80</sub>H<sub>140</sub>N<sub>17</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 521.0250, found 521.0247; calcd for C<sub>80</sub>H<sub>141</sub>N<sub>17</sub>O<sub>14</sub> [M + 4H]<sup>4+</sup> 391.0205, found 391.0199.

### **Ac-Lys-Lys-Leu-Phe-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP373)**

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (80:20) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP373**) in >99%

purity.  $t_R = 7.94$  min. MS (ESI)  $m/z$ : 781.6  $[M + 2H]^{2+}$ , 1561.1  $[M + H]^+$ , 1583.1  $[M + Na]^+$ ; HRMS (ESI)  $m/z$ : calcd for  $C_{80}H_{139}N_{17}O_{14}$   $[M + 2H]^{2+}$  781.0338, found 781.0330; calcd for  $C_{80}H_{140}N_{17}O_{14}$   $[M + 3H]^{3+}$  521.0250, found 521.0244.

**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP374)**

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (80:20) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP374) in >99% purity.  $t_R = 6.91$  min. MS (ESI)  $m/z$ : 789.1  $[M + 2H]^{2+}$ , 1577.1  $[M + H]^+$ , 1598.1  $[M + Na]^+$ ; HRMS (ESI)  $m/z$ : calcd for  $C_{80}H_{140}N_{18}O_{14}$   $[M + 2H]^{2+}$  788.5393, found 788.5393; calcd for  $C_{80}H_{141}N_{18}O_{14}$   $[M + 3H]^{3+}$  526.0286, found 526.0284; calcd for  $C_{80}H_{142}N_{18}O_{14}$   $[M + 4H]^{4+}$  394.7733, found 394.7733.

**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Lys(COC<sub>5</sub>H<sub>11</sub>)-Lys-Tyr-Leu-NH<sub>2</sub> (BP375)**

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Lys(COC<sub>5</sub>H<sub>11</sub>)-Lys-Tyr-Leu-NH<sub>2</sub> (BP375) in >99% purity.  $t_R = 7.17$  min. MS (ESI)  $m/z$ : 789.1  $[M + 2H]^{2+}$ , 1577.1  $[M + H]^+$ , 1599.1  $[M + Na]^+$ ; HRMS (ESI)  $m/z$ : calcd for  $C_{80}H_{140}N_{18}O_{14}$   $[M + 2H]^{2+}$  788.5393, found 788.5383; calcd for  $C_{80}H_{141}N_{18}O_{14}$   $[M + 3H]^{3+}$  526.0286, found 526.0276; calcd for  $C_{80}H_{142}N_{18}O_{14}$   $[M + 4H]^{4+}$  394.7733, found 394.7729.

**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys(COC<sub>5</sub>H<sub>11</sub>)-Tyr-Leu-NH<sub>2</sub> (BP376)**

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (70:30) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys(COC<sub>5</sub>H<sub>11</sub>)-Tyr-Leu-NH<sub>2</sub> (BP376) in >99% purity.  $t_R = 7.48$  min. MS (ESI)  $m/z$ : 781.6  $[M + 2H]^{2+}$ , 1561.1  $[M + H]^+$ , 1583.1  $[M + Na]^+$ ; HRMS (ESI)  $m/z$ : calcd for  $C_{80}H_{139}N_{17}O_{14}$   $[M + 2H]^{2+}$  781.0338, found 781.0311; calcd for  $C_{80}H_{140}N_{17}O_{14}$   $[M + 3H]^{3+}$  521.0250, found 521.0233.

**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Leu-NH<sub>2</sub> (BP377)**

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Leu-NH<sub>2</sub> (BP377) in >99% purity.  $t_R = 7.58$  min. MS (ESI)  $m/z$ : 763.6 [M + 2H]<sup>2+</sup>, 1526.2 [M + H]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for C<sub>77</sub>H<sub>142</sub>N<sub>18</sub>O<sub>13</sub> [M + 2H]<sup>2+</sup> 763.5496, found 763.5486; calcd for C<sub>77</sub>H<sub>143</sub>N<sub>18</sub>O<sub>13</sub> [M + 3H]<sup>3+</sup> 509.3689, found 509.3700; calcd for C<sub>77</sub>H<sub>144</sub>N<sub>18</sub>O<sub>13</sub> [M + 4H]<sup>4+</sup> 382.2785, found 382.2791.

**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC<sub>5</sub>H<sub>11</sub>)-NH<sub>2</sub> (BP378)**

This lipopeptide was prepared following the procedure described in the manuscript using hexanoic acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (80:20) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC<sub>5</sub>H<sub>11</sub>)-NH<sub>2</sub> (BP378) in >99% purity.  $t_R = 6.96$  min. MS (ESI)  $m/z$ : 788.6 [M + 2H]<sup>2+</sup>, 1577.1 [M + H]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for C<sub>80</sub>H<sub>140</sub>N<sub>18</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 788.5393, found 788.5396; calcd for C<sub>80</sub>H<sub>141</sub>N<sub>18</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 526.0286, found 526.0308; calcd for C<sub>80</sub>H<sub>142</sub>N<sub>18</sub>O<sub>14</sub> [M + 4H]<sup>4+</sup> 394.7733, found 394.7742.

**C<sub>3</sub>H<sub>7</sub>CO-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP379)**

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded C<sub>3</sub>H<sub>7</sub>CO-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP379) in >99% purity.  $t_R = 7.52$  min. MS (ESI)  $m/z$ : 746.0 [M + 2H]<sup>2+</sup>, 1491.1 [M + H]<sup>+</sup>, 1513.1 [M + Na]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for C<sub>76</sub>H<sub>133</sub>N<sub>17</sub>O<sub>13</sub> [M + 2H]<sup>2+</sup> 746.0129, found 746.0102; calcd for C<sub>76</sub>H<sub>134</sub>N<sub>17</sub>O<sub>13</sub> [M + 3H]<sup>3+</sup> 497.6777, found 497.6770; calcd for C<sub>76</sub>H<sub>135</sub>N<sub>17</sub>O<sub>13</sub> [M + 4H]<sup>4+</sup> 373.5101, found 373.5104.

**Ac-Lys(COC<sub>3</sub>H<sub>7</sub>)-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP380)**

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (70:30) afforded Ac-Lys(COC<sub>3</sub>H<sub>7</sub>)-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP380) in >99% purity.  $t_R = 7.79$  min. MS (ESI)  $m/z$ : 1533.3 [M + H]<sup>+</sup>, 1555.3 [M + Na]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for



$C_{78}H_{135}N_{17}O_{14}$   $[M + 2H]^{2+}$  767.0182, found 767.0158; calcd for  $C_{78}H_{136}N_{17}O_{14}$   $[M + 3H]^{3+}$  511.6812, found 511.6805; calcd for  $C_{78}H_{137}N_{17}O_{14}$   $[M + 4H]^{4+}$  384.0127, found 384.0117.

**Ac-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP381)**

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (80:20) afforded Ac-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP381**) in >99% purity.  $t_R$  = 6.96 min. MS (ESI)  $m/z$ : 511.9  $[M + 3H]^{3+}$ , 767.5  $[M + 2H]^{2+}$ , 1533.1  $[M + H]^+$ , 1555.3  $[M + Na]^+$ ; HRMS (ESI)  $m/z$ : calcd for  $C_{78}H_{135}N_{17}O_{14}$   $[M + 2H]^{2+}$  767.0182, found 767.0160; calcd for  $C_{78}H_{136}N_{17}O_{14}$   $[M + 3H]^{3+}$  511.6812, found 511.6803; calcd for  $C_{78}H_{137}N_{17}O_{14}$   $[M + 4H]^{4+}$  384.0127, found 384.0119.

**Ac-Lys-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP382)**

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (80:20) afforded Ac-Lys-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP382**) in >99% purity.  $t_R$  = 6.91 min. MS (ESI)  $m/z$ : 1548.2  $[M + H]^+$ ; HRMS (ESI)  $m/z$ : calcd for  $C_{80}H_{136}N_{18}O_{14}$   $[M + 2H]^{2+}$  774.5236, found 774.5220; calcd for  $C_{78}H_{137}N_{18}O_{14}$   $[M + 3H]^{3+}$  516.6848, found 516.6845; calcd for  $C_{78}H_{138}N_{18}O_{14}$   $[M + 4H]^{4+}$  387.7654, found 387.7648.

**Ac-Lys-Lys-Leu-Lys(COC<sub>3</sub>H<sub>7</sub>)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP383)**

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (80:20) afforded Ac-Lys-Lys-Leu-Lys(COC<sub>3</sub>H<sub>7</sub>)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP383**) in >99% purity.  $t_R$  = 6.41 min. MS (ESI)  $m/z$ : 1514.2  $[M + H]^+$ , 1536.1  $[M + Na]^+$ ; HRMS (ESI)  $m/z$ : calcd for  $C_{75}H_{137}N_{18}O_{14}$   $[M + H]^+$  1514.0556, found 1514.0535; calcd for  $C_{75}H_{138}N_{17}O_{14}$   $[M + 2H]^{2+}$  757.5314, found 757.5312.

**Ac-Lys-Lys-Leu-Phe-Lys(COC<sub>3</sub>H<sub>7</sub>)-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP384)**

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded Ac-Lys-Lys-Leu-Phe-Lys(COC<sub>3</sub>H<sub>7</sub>)-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP384**) in >99% purity. *t<sub>R</sub>* = 6.91 min. MS (ESI) *m/z*: 1533.2 [M + H]<sup>+</sup>, 1555.2 [M + Na]<sup>+</sup>; HRMS (ESI) *m/z*: calcd for C<sub>78</sub>H<sub>135</sub>N<sub>17</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 767.0182, found 767.0158; calcd for C<sub>78</sub>H<sub>136</sub>N<sub>17</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 511.6812, found 511.6821; calcd for C<sub>78</sub>H<sub>137</sub>N<sub>17</sub>O<sub>14</sub> [M + 4H]<sup>4+</sup> 384.0127, found 384.0114.

**Ac-Lys-Lys-Leu-Phe-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP385)**

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP385**) in >99% purity. *t<sub>R</sub>* = 7.02 min. MS (ESI) *m/z*: 1533.2 [M + H]<sup>+</sup>, 1555.1 [M + Na]<sup>+</sup>; HRMS (ESI) *m/z*: calcd for C<sub>78</sub>H<sub>135</sub>N<sub>17</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 767.0182, found 767.0189; calcd for C<sub>78</sub>H<sub>136</sub>N<sub>17</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 511.6812, found 511.6818; calcd for C<sub>78</sub>H<sub>137</sub>N<sub>17</sub>O<sub>14</sub> [M + 4H]<sup>4+</sup> 384.0127, found 384.0140.

**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP386)**

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (85:15) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP386**) in >99% purity. *t<sub>R</sub>* = 6.25 min. MS (ESI) *m/z*: 1548.2 [M + H]<sup>+</sup>, 1570.1 [M + Na]<sup>+</sup>; HRMS (ESI) *m/z*: calcd for C<sub>78</sub>H<sub>136</sub>N<sub>18</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 774.5236, found 774.5234; calcd for C<sub>78</sub>H<sub>137</sub>N<sub>18</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 516.6848, found 516.6867; calcd for C<sub>78</sub>H<sub>138</sub>N<sub>18</sub>O<sub>14</sub> [M + 4H]<sup>4+</sup> 387.7654, found 387.7666.

**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Lys(COC<sub>3</sub>H<sub>7</sub>)-Lys-Tyr-Leu-NH<sub>2</sub> (BP387)**

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (80:20) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Lys(COC<sub>3</sub>H<sub>7</sub>)-Lys-Tyr-Leu-NH<sub>2</sub> (**BP387**) in >99% purity. *t<sub>R</sub>* = 6.49 min. MS (ESI) *m/z*: 774.5 [M + 2H]<sup>2+</sup>, 1549.0 [M + H]<sup>+</sup>; HRMS (ESI) *m/z*: calcd for

$C_{78}H_{137}N_{18}O_{14} [M + 3H]^{3+}$  516.6848, found 516.6839; calcd for  $C_{78}H_{138}N_{18}O_{14} [M + 4H]^{4+}$  387.7654, found 387.7648.

**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys(COC<sub>3</sub>H<sub>7</sub>)-Tyr-Leu-NH<sub>2</sub> (BP388)**

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys(COC<sub>3</sub>H<sub>7</sub>)-Tyr-Leu-NH<sub>2</sub> (**BP388**) in >99% purity.  $t_R$  = 6.80 min. MS (ESI)  $m/z$ : 767.1 [M + 2H]<sup>2+</sup>, 1533.1 [M + H]<sup>+</sup>, 1555.1 [M + Na]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for  $C_{78}H_{134}N_{17}O_{14}Na [M + H + Na]^{2+}$  778.0091, found 778.0070; calcd for  $C_{78}H_{135}N_{17}O_{14} [M + 2H]^{2+}$  767.0182, found 767.0160; calcd for  $C_{78}H_{135}N_{17}O_{14}Na [M + 2H + Na]^{3+}$  519.0085, found 519.0070; calcd for  $C_{78}H_{136}N_{17}O_{14} [M + 3H]^{3+}$  511.6812, found 511.6805.

**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Leu-NH<sub>2</sub> (BP389)**

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Leu-NH<sub>2</sub> (**BP389**) in >99% purity.  $t_R$  = 6.73 min. MS (ESI)  $m/z$ : 1498.2 [M + H]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for  $C_{75}H_{138}N_{18}O_{13} [M + 2H]^{2+}$  749.5340, found 749.5328; calcd for  $C_{75}H_{139}N_{18}O_{13} [M + 3H]^{3+}$  500.0251, found 500.0268; calcd for  $C_{75}H_{140}N_{18}O_{13} [M + 4H]^{4+}$  375.2706, found 375.2692.

**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC<sub>3</sub>H<sub>7</sub>)-NH<sub>2</sub> (BP390)**

This lipopeptide was prepared following the procedure described in the manuscript using butyric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (80:20) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC<sub>3</sub>H<sub>7</sub>)-NH<sub>2</sub> (**BP390**) in >99% purity.  $t_R$  = 6.27 min. MS (ESI)  $m/z$ : 516.7 [M + 3H]<sup>3+</sup>, 774.6 [M + 2H]<sup>2+</sup>, 1548.2 [M + H]<sup>+</sup>, 1570.1 [M + Na]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for  $C_{86}H_{136}N_{18}O_{14} [M + 2H]^{2+}$  774.5236, found 774.5216; calcd for  $C_{78}H_{137}N_{18}O_{14} [M + 3H]^{3+}$  516.6848, found 516.6843; calcd for  $C_{78}H_{138}N_{18}O_{14} [M + 4H]^{4+}$  387.7654, found 387.7665.

### **C<sub>11</sub>H<sub>23</sub>CO-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP391)**

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (70:30) afforded C<sub>11</sub>H<sub>23</sub>CO-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP391**) in >99% purity. *t<sub>R</sub>* = 8.06 min. MS (ESI) *m/z*: 535.4 [M + 3H]<sup>3+</sup>, 802.6 [H + 2H]<sup>2+</sup>, 1604.2 [M + H]<sup>+</sup>; HRMS (ESI) *m/z*: calcd for C<sub>84</sub>H<sub>149</sub>N<sub>17</sub>O<sub>13</sub> [M + 2H]<sup>2+</sup> 802.0755, found 802.0738; calcd for C<sub>84</sub>H<sub>150</sub>N<sub>17</sub>O<sub>13</sub> [M + 3H]<sup>3+</sup> 535.0528, found 535.0527; calcd for C<sub>84</sub>H<sub>151</sub>N<sub>17</sub>O<sub>13</sub> [M + 4H]<sup>4+</sup> 401.5414, found 401.5427.

### **Ac-Lys(COC<sub>11</sub>H<sub>23</sub>)-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP392)**

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (70:30) afforded Ac-Lys(COC<sub>11</sub>H<sub>23</sub>)-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP392**) in >99% purity. *t<sub>R</sub>* = 8.25 min. MS (ESI) *m/z*: 549.1 [M + 3H]<sup>3+</sup>, 823.1 [M + 2H]<sup>2+</sup>, 1646.2 [M + H]<sup>+</sup>; HRMS (ESI) *m/z*: calcd for C<sub>86</sub>H<sub>151</sub>N<sub>17</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 823.0808, found 823.0808; calcd for C<sub>86</sub>H<sub>152</sub>N<sub>17</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 549.0563, found 549.0558; calcd for C<sub>86</sub>H<sub>153</sub>N<sub>17</sub>O<sub>14</sub> [M + 4H]<sup>4+</sup> 412.0440, found 412.0437.

### **Ac-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP393)**

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (80:20) afforded Ac-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP393**) in >99% purity. *t<sub>R</sub>* = 7.68 min. MS (ESI) *m/z*: 549.3 [M + 3H]<sup>3+</sup>, 823.5 [M + 2H]<sup>2+</sup>, 1645.3 [M + H]<sup>+</sup>, 1667.1 [M + Na]<sup>+</sup>; HRMS (ESI) *m/z*: calcd for C<sub>86</sub>H<sub>151</sub>N<sub>17</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 823.0808, found 823.0789; calcd for C<sub>86</sub>H<sub>152</sub>N<sub>17</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 549.0563, found 549.0548.

### **Ac-Lys-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP394)**

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded Ac-Lys-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP394**) in 97% purity. *t<sub>R</sub>* = 7.32 min. MS (ESI) *m/z*: 554.1 [M + 3H]<sup>3+</sup>, 831.1 [M + 2H]<sup>2+</sup>, 1661.3 [M + H]<sup>+</sup>, 1683.3 [M + Na]<sup>+</sup>;

HRMS (ESI)  $m/z$ : calcd for  $C_{86}H_{152}N_{18}O_{14}$   $[M + 2H]^{2+}$  830.5862, found 830.5847; calcd for  $C_{86}H_{153}N_{18}O_{14}$   $[M + 3H]^{3+}$  554.0599, found 554.0601; calcd for  $C_{86}H_{154}N_{18}O_{14}$   $[M + 4H]^{4+}$  415.7967, found 415.7987.

**Ac-Lys-Lys-Leu-Lys(COC<sub>11</sub>H<sub>23</sub>)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP395)**

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded Ac-Lys-Lys-Leu-Lys(COC<sub>11</sub>H<sub>23</sub>)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP395**) in >99% purity.  $t_R$  = 7.39 min. MS (ESI)  $m/z$ : 1627.3  $[M + H]^+$ ; HRMS (ESI)  $m/z$ : calcd for  $C_{83}H_{153}N_{18}O_{14}$   $[M + H]^+$  1626.1808, found 1626.1755; calcd for  $C_{83}H_{154}N_{18}O_{14}$   $[M + 2H]^{2+}$  813.5940, found 813.5911.

**Ac-Lys-Lys-Leu-Phe-Lys(COC<sub>11</sub>H<sub>23</sub>)-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP396)**

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (70:30) afforded Ac-Lys-Lys-Leu-Phe-Lys(COC<sub>11</sub>H<sub>23</sub>)-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP396**) in >99% purity.  $t_R$  = 7.76 min. MS (ESI)  $m/z$ : 549.4  $[M + 3H]^{3+}$ , 823.1  $[M + 2H]^{2+}$ , 1646.3  $[M + H]^+$ ; HRMS (ESI)  $m/z$ : calcd for  $C_{86}H_{151}N_{17}O_{14}$   $[M + 2H]^{2+}$  823.0808, found 823.0791; calcd for  $C_{86}H_{152}N_{17}O_{14}$   $[M + 3H]^{3+}$  549.0563, found 549.0570; calcd for  $C_{86}H_{153}N_{17}O_{14}$   $[M + 4H]^{4+}$  412.0440, found 412.0432.

**Ac-Lys-Lys-Leu-Phe-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP397)**

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (70:30) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP397**) in 97% purity.  $t_R$  = 8.10 min. MS (ESI)  $m/z$ : 549.4  $[M + 3H]^{3+}$ , 823.1  $[M + 2H]^{2+}$ , 1646.3  $[M + H]^+$ ; HRMS (ESI)  $m/z$ : calcd for  $C_{86}H_{151}N_{17}O_{14}$   $[M + 2H]^{2+}$  823.0808, found 823.0806; calcd for  $C_{86}H_{152}N_{17}O_{14}$   $[M + 3H]^{3+}$  549.0563, found 549.0586; calcd for  $C_{86}H_{153}N_{17}O_{14}$   $[M + 4H]^{4+}$  412.0440, found 412.0444.

#### **Ac-Lys-Lys-Leu-Phe-Lys-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP398)**

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (80:20) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (**BP398**) in >99% purity.  $t_R$  = 7.26 min. MS (ESI)  $m/z$ : 554.1 [M + 3H]<sup>3+</sup>, 830.6 [M + 2H]<sup>2+</sup>, 1660.3 [M + H]<sup>+</sup>, 1682.3 [M + Na]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for C<sub>86</sub>H<sub>152</sub>N<sub>18</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 830.5862, found 830.5852; calcd for C<sub>86</sub>H<sub>153</sub>N<sub>18</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 554.0599, found 554.0602; calcd for C<sub>86</sub>H<sub>154</sub>N<sub>18</sub>O<sub>14</sub> [M + 4H]<sup>4+</sup> 415.7967, found 415.7972.

#### **Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Lys(COC<sub>11</sub>H<sub>23</sub>)-Lys-Tyr-Leu-NH<sub>2</sub> (BP399)**

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Lys(COC<sub>11</sub>H<sub>23</sub>)-Lys-Tyr-Leu-NH<sub>2</sub> (**BP399**) in >99% purity.  $t_R$  = 7.38 min. MS (ESI)  $m/z$ : 554.1 [M + 3H]<sup>3+</sup>, 831.1 [M + 2H]<sup>2+</sup>, 1660.3 [M + H]<sup>+</sup>, 1682.3 [M + Na]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for C<sub>86</sub>H<sub>152</sub>N<sub>18</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 830.5862, found 830.5847; calcd for C<sub>86</sub>H<sub>153</sub>N<sub>18</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 554.0599, found 554.0593; calcd for C<sub>86</sub>H<sub>154</sub>N<sub>18</sub>O<sub>14</sub> [M + 4H]<sup>4+</sup> 415.7967, found 415.7968.

#### **Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys(COC<sub>11</sub>H<sub>23</sub>)-Tyr-Leu-NH<sub>2</sub> (BP400)**

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys(COC<sub>11</sub>H<sub>23</sub>)-Tyr-Leu-NH<sub>2</sub> (**BP400**) in >99% purity.  $t_R$  = 7.60 min. MS (ESI)  $m/z$ : 823.1 [M + 2H]<sup>2+</sup>, 1645.3 [M + H]<sup>+</sup>, 1667.3 [M + Na]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for C<sub>86</sub>H<sub>151</sub>N<sub>17</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 823.0808, found 823.0796; calcd for C<sub>86</sub>H<sub>152</sub>N<sub>17</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 549.0563, found 549.0565; calcd for C<sub>86</sub>H<sub>153</sub>N<sub>17</sub>O<sub>14</sub> [M + 4H]<sup>4+</sup> 412.0440, found 412.0434.

#### **Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Leu-NH<sub>2</sub> (BP401)**

This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded


Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Leu-NH<sub>2</sub> (**BP401**) in >99% purity.  $t_R = 7.77$  min. MS (ESI)  $m/z$ : 537.5 [M + 3H]<sup>3+</sup>, 806.1 [M + 2H]<sup>2+</sup>, 1610.3 [M + H]<sup>+</sup>, 1632.3 [M + Na]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for C<sub>83</sub>H<sub>154</sub>N<sub>18</sub>O<sub>13</sub> [M + 2H]<sup>2+</sup> 805.5966, found 805.5955; calcd for C<sub>83</sub>H<sub>155</sub>N<sub>18</sub>O<sub>13</sub> [M + 3H]<sup>3+</sup> 537.4002, found 537.3999; calcd for C<sub>83</sub>H<sub>156</sub>N<sub>18</sub>O<sub>13</sub> [M + 4H]<sup>4+</sup> 403.3019, found 403.3019.

**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC<sub>11</sub>H<sub>23</sub>)-NH<sub>2</sub> (BP402)**


This lipopeptide was prepared following the procedure described in the manuscript using lauric acid. Acidolytic cleavage of the resulting resin and purification eluting with H<sub>2</sub>O/CH<sub>3</sub>CN (75:25) afforded Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC<sub>11</sub>H<sub>23</sub>)-NH<sub>2</sub> (**BP402**) in 99% purity.  $t_R = 7.29$  min. MS (ESI)  $m/z$ : 554.4 [M + 3H]<sup>3+</sup>, 831.1 [M + 2H]<sup>2+</sup>, 1661.3 [M + H]<sup>+</sup>; HRMS (ESI)  $m/z$ : calcd for C<sub>86</sub>H<sub>152</sub>N<sub>18</sub>O<sub>14</sub> [M + 2H]<sup>2+</sup> 830.5862, found 830.5866; calcd for C<sub>86</sub>H<sub>153</sub>N<sub>18</sub>O<sub>14</sub> [M + 3H]<sup>3+</sup> 554.0599, found 554.0601; calcd for C<sub>86</sub>H<sub>154</sub>N<sub>18</sub>O<sub>14</sub> [M + 4H]<sup>4+</sup> 415.7967, found 415.7969.

### 3. Characterization of lipopeptides BP367-BP402: HPLC of crude and purified lipopeptides, ESI-MS and HRMS

#### C<sub>5</sub>H<sub>11</sub>CO-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP367)




HPLC of crude peptide ( $\lambda=220$  nm)



No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,49	43,350	2,553	3,25
2	6,60	32,810	2,437	3,11
3	6,96	14,730	1,697	2,16
4	7,77	782,429	60,517	77,13
5	7,84	176,586	9,122	11,63
6	8,10	15,984	0,862	1,10
7	8,22	19,823	1,277	1,63
Total:		1085,712	78,465	100,00




## HPLC of purified peptide ( $\lambda=220$ nm)








No.	Ret. Time (detected) min	Height mAU	Area mAU*min	Rel. Area %
1	7,77	525,723	39,635	100,00
Total:		525,723	39,635	100,00

## ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**Ac-Lys(COC<sub>5</sub>H<sub>11</sub>)-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP368)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret. Time (detected) min	Height mAU	Area mAU*min	Rel. Area %
1	7,48	60,911	4,478	56,85
2	7,60	32,697	2,633	33,43
3	7,89	9,958	0,765	9,72
Total:		103,566	7,877	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,91	240,601	18,423	100,00
Total:		240,601	18,423	100,00


### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )



**Ac-Lys(COC<sub>5</sub>H<sub>11</sub>)-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP369)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,29	690,240	57,590	62,04
2	7,56	367,199	26,591	28,65
3	7,68	114,437	8,641	9,31
Total:		1171,877	92,822	100,00

## HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,34	15,021	1,526	8,06
2	7,53	241,900	17,408	91,94
Total:		256,921	18,934	100,00


## ESI-MS ( $m/z$ )






# HRMS ( $m/z$ )






**Ac-Lys-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP370)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,66	17,474	0,994	2,57
2	7,06	389,607	30,135	77,87
3	7,39	90,027	7,572	19,57
Total:		497,108	38,701	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)








No.	Ret. Time (detected) min	Height mAU	Area mAU*min	Rel. Area %
1	7,06	260,633	19,695	100,00
Total:		260,633	19,695	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






Ac-Lys-Lys-Leu-Lys(COC<sub>5</sub>H<sub>11</sub>)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP371)




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,69	24,367	1,155	0,93
2	7,10	1213,823	97,208	77,85
3	7,30	81,648	5,491	4,40
4	7,47	245,014	16,765	13,43
5	8,11	71,929	4,245	3,40
Total:		1636,782	124,863	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret. Time (detected) min	Height mAU	Area mAU*min	Rel. Area %
1	7,11	294,893	21,782	100,00
Total:		294,893	21,782	100,00


### ESI-MS ( $m/z$ )






# HRMS ( $m/z$ )






**Ac-Lys-Lys-Leu-Phe-Lys(COC<sub>5</sub>H<sub>7</sub>)-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP372)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,41	47,935	4,595	2,52
2	7,61	1340,772	118,085	64,77
3	7,75	485,876	39,491	21,66
4	8,05	205,759	15,107	8,29
5	8,79	66,449	5,022	2,75
Total:		2146,790	182,300	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,64	558,375	42,439	100,00
Total:		558,375	42,439	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**Ac-Lys-Lys-Leu-Phe-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP373)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU <sup>2</sup> min	Rel.Area %
1	7,95	1332,447	118,517	75,92
2	8,23	340,877	37,595	24,08
Total:		1673,324	156,113	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,94	612,471	49,315	100,00
Total:		612,471	49,315	100,00

### ESI-MS ( $m/z$ )







# HRMS ( $m/z$ )



**Ac-Lys-Lys-Leu-Phe-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP374)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret. Time (detected) min	Height mAU	Area mAU*min	Rel. Area %
1	6,96	133,525	9,002	68,96
2	7,05	26,348	1,253	9,60
3	7,33	24,700	1,724	13,20
4	8,19	15,596	1,075	8,23
Total:		200,170	13,054	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,91	1158,422	95,276	100,00
Total:		1158,422	95,276	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Lys(COC<sub>5</sub>H<sub>11</sub>)-Lys-Tyr-Leu-NH<sub>2</sub> (BP375)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,18	434,330	31,911	75,93
2	7,45	132,639	10,117	24,07
Total:		566,969	42,028	100,00

## HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,17	491,684	34,711	100,00
Total:		491,684	34,711	100,00


## ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )








**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys(COC<sub>5</sub>H<sub>11</sub>)-Tyr-Leu-NH<sub>2</sub> (BP376)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,45	1536,958	155,833	87,70
2	7,79	298,985	21,863	12,30
Total:		1835,943	177,696	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,48	574,445	47,224	100,00
Total:		574,445	47,224	100,00


### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )



**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Lys(COC<sub>5</sub>H<sub>11</sub>)-Leu-NH<sub>2</sub> (BP377)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,47	918,568	86,749	73,19
2	7,74	430,457	31,783	26,81
Total:		1349,025	118,532	100,00

## HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,58	234,918	17,199	100,00
Total:		234,918	17,199	100,00

## ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )








**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC<sub>5</sub>H<sub>11</sub>)-NH<sub>2</sub> (BP378)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,96	312,376	27,209	68,48
2	7,19	77,522	5,774	14,53
3	7,36	36,021	1,980	4,98
4	7,59	23,610	1,467	3,69
5	7,99	20,581	1,420	3,57
6	8,15	24,528	1,881	4,73
Total:		494,638	39,730	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret. Time (detected) min	Height mAU	Area mAU*min	Rel. Area %
1	6,96	564,325	40,841	100,00
Total:		564,325	40,841	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**C<sub>3</sub>H<sub>7</sub>CO-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP379)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,56	343,351	26,903	90,82
2	7,72	39,891	2,718	9,18
Total:		383,242	29,621	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret. Time (detected) min	Height mAU	Area mAU*min	Rel. Area %
1	7,52	535,647	38,742	100,00
Total:		535,647	38,742	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )








**Ac-Lys(COC<sub>3</sub>H<sub>7</sub>)-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP380)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,48	13,940	1,010	4,86
2	7,63	7,761	0,816	3,93
3	7,83	186,064	15,078	72,59
4	8,35	44,933	3,866	18,61
Total:		252,699	20,770	100,00

## HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret. Time (detected) min	Height mAU	Area mAU*min	Rel. Area %
1	7,79	738,105	57,784	100,00
Total:		738,105	57,784	100,00

## ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**Ac-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP381)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,88	491,197	18,143	9,03
2	6,95	1312,045	134,699	67,01
3	7,21	480,384	48,178	23,97
Total:		2283,626	201,020	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)








No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,96	1109,076	100,505	100,00
Total:		1109,076	100,505	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )








**Ac-Lys-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP382)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,78	7,516	0,551	2,18
2	6,94	248,872	19,212	75,96
3	7,22	10,420	0,588	2,32
4	7,53	48,490	3,767	14,89
5	7,82	16,044	1,176	4,65
Total:		331,343	25,293	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret. Time (detected) min	Height mAU	Area mAU*min	Rel. Area %
1	6,91	267,492	17,120	100,00
Total:		267,492	17,120	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**Ac-Lys-Lys-Leu-Lys(COC<sub>3</sub>H<sub>7</sub>)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP383)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret. Time (detected) min	Height mAU	Area mAU*min	Rel. Area %
1	6,43	240,285	19,131	82,31
2	6,94	55,808	4,112	17,69
Total:		296,093	23,243	100,00

## HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,41	995,875	73,746	100,00
Total:		995,875	73,746	100,00

## ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )








**Ac-Lys-Lys-Leu-Phe-Lys(COC<sub>3</sub>H<sub>7</sub>)-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP384)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,91	426,920	27,025	66,79
2	6,98	112,434	3,823	9,45
3	7,14	112,964	5,513	13,62
4	7,17	73,501	4,103	10,14
Total:		725,818	40,463	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret. Time (detected) min	Height mAU	Area mAU*min	Rel. Area %
1	6,91	931,844	70,418	100,00
Total:		931,844	70,418	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**Ac-Lys-Lys-Leu-Phe-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP385)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	2,67	24,266	3,591	5,79
2	7,04	592,498	48,281	77,83
3	7,31	45,100	2,200	3,55
4	7,44	122,228	7,962	12,83
Total:		784,093	62,033	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret. Time (detected) min	Height mAU	Area mAU*min	Rel. Area %
1	7,02	795,497	59,612	100,00
Total:		795,497	59,612	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )








**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP386)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,25	592,905	38,948	70,32
2	6,34	108,977	5,107	9,22
3	6,78	129,662	9,529	17,20
4	7,80	33,947	1,805	3,26
Total:		865,491	55,388	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,25	405,383	28,199	100,00
Total:		405,383	28,199	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Lys(COC<sub>3</sub>H<sub>7</sub>)-Lys-Tyr-Leu-NH<sub>2</sub> (BP387)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU <sup>2</sup> min	Rel.Area %
1	6,48	1641,202	103,705	59,43
2	6,54	662,273	25,655	14,70
3	6,88	470,800	35,575	20,39
4	7,33	99,025	6,624	3,80
5	7,82	62,032	2,926	1,68
Total:		2935,332	174,486	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret. Time (detected) min	Height mAU	Area mAU*min	Rel. Area %
1	6,49	614,564	41,220	100,00
Total:		614,564	41,220	100,00


### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )



**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys(COC<sub>3</sub>H<sub>7</sub>)-Tyr-Leu-NH<sub>2</sub> (BP388)**




HPLC of crude peptide ( $\lambda=220$  nm)



No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,81	734,597	55,356	71,07
2	6,96	202,939	12,415	15,94
3	7,08	96,940	6,299	8,09
4	7,87	32,676	3,822	4,91
Total:		1067,152	77,893	100,00




## HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,80	1043,690	77,975	100,00
Total:		1043,690	77,975	100,00


## ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )



**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Lys(COC<sub>3</sub>H<sub>7</sub>)-Leu-NH<sub>2</sub> (BP389)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	2,78	11,120	3,623	9,81
2	6,74	304,240	23,356	63,24
3	6,96	49,294	2,872	7,78
4	7,17	75,149	5,192	14,06
5	7,71	18,724	1,088	2,95
6	7,82	19,966	0,802	2,17
Total:		478,493	36,934	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,73	652,224	47,088	100,00
Total:		652,224	47,088	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC<sub>3</sub>H<sub>7</sub>)-NH<sub>2</sub> (BP390)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,28	1011,506	57,532	39,69
2	6,32	444,995	26,334	18,17
3	6,45	290,645	16,081	11,09
4	6,52	146,149	7,347	5,07
5	6,65	67,035	4,255	2,94
6	6,82	195,858	15,276	10,54
7	7,15	48,894	7,528	5,19
8	7,36	21,532	1,052	0,73
9	7,71	34,648	1,810	1,25
10	7,82	110,083	7,753	5,35
Total:		2371,346	144,969	100,00

## HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,27	1068,134	76,691	100,00
Total:		1068,134	76,691	100,00


## ESI-MS ( $m/z$ )






# HRMS ( $m/z$ )






**C<sub>11</sub>H<sub>23</sub>CO-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP391)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	8,11	746,197	78,152	84,86
2	8,26	168,248	13,942	15,14
Total:		914,445	92,093	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	8,06	371,606	32,445	100,00
Total:		371,606	32,445	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**Ac-Lys(COC<sub>11</sub>H<sub>23</sub>)-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP392)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,85	34,448	1,872	4,00
2	6,94	19,777	1,534	3,28
3	7,53	116,711	9,544	20,39
4	8,32	343,030	33,847	72,33
Total:		513,966	46,798	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	8,25	327,932	26,627	100,00
Total:		327,932	26,627	100,00


### ESI-MS ( $m/z$ )






# HRMS ( $m/z$ )






**Ac-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP393)**




HPLC of crude peptide ( $\lambda=220$  nm)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.712	W R	0.0591	1917.23145	455.58569	19.8588
2	7.664	VB R	0.0773	7394.40186	1301.64868	76.5917
3	8.541	VB	0.0989	342.67871	48.83156	3.5495


Totals : 9654.31201 1806.06593

### HPLC of purified peptide ( $\lambda=220$ nm)






Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.685	BV R	0.0748	5476.25000	1001.53162	100.0000
Totals :				5476.25000	1001.53162	


### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )



**Ac-Lys-Lys(Lys(COC<sub>11</sub>H<sub>23</sub>))-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP394)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,28	16,698	0,824	1,06
2	6,89	188,087	13,325	17,19
3	7,37	709,203	61,388	79,19
4	7,73	33,524	1,979	2,55
Total:		947,512	77,516	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,32	748,607	69,484	96,84
2	8,71	37,432	2,269	3,16
Total:		786,039	71,753	100,00


### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )








**Ac-Lys-Lys-Leu-Lys(COC<sub>11</sub>H<sub>23</sub>)-Lys-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP395)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	2,41	26,660	6,826	7,56
2	6,92	169,022	16,254	18,00
3	7,37	611,413	59,858	66,28
4	7,64	45,647	4,813	5,33
5	7,82	38,161	2,564	2,84
Total:		890,902	90,316	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,39	269,946	23,056	100,00
Total:		269,946	23,056	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**Ac-Lys-Lys-Leu-Phe-Lys(COC<sub>11</sub>H<sub>23</sub>)-Lys-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP396)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,13	823,490	65,569	22,07
2	7,72	1572,407	206,739	69,60
3	8,32	210,668	14,235	4,79
4	8,93	137,039	10,506	3,54
Total:		2743,604	297,049	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,76	553,498	51,363	100,00
Total:		553,498	51,363	100,00


### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )








**Ac-Lys-Lys-Leu-Phe-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Ile-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP397)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,41	249,174	20,133	18,19
2	7,69	25,870	1,525	1,38
3	7,81	27,742	1,394	1,26
4	8,08	796,771	81,638	73,74
5	8,53	80,745	6,016	5,43
Total:		1180,302	110,706	100,00

## HPLC of purified peptide ( $\lambda=220$ nm)









No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,68	15,962	0,995	2,51
2	8,10	452,427	38,610	97,49
Total:		468,389	39,606	100,00

## ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Leu-Lys-Tyr-Leu-NH<sub>2</sub> (BP398)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,79	255,948	19,043	16,63
2	7,25	941,040	92,119	80,44
3	7,84	46,558	3,356	2,93
Total:		1243,546	114,517	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,26	666,796	56,101	100,00
Total:		666,796	56,101	100,00


### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )








**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Lys(COC<sub>11</sub>H<sub>23</sub>)-Lys-Tyr-Leu-NH<sub>2</sub> (BP399)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,87	572,985	47,760	17,15
2	7,09	71,293	8,638	3,10
3	7,36	1538,740	184,103	66,12
4	7,70	173,523	16,079	5,77
5	7,84	210,519	14,740	5,29
6	8,43	86,993	7,105	2,55
Total:		2654,054	278,426	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)









No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,38	705,265	64,787	100,00
Total:		705,265	64,787	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys(COC<sub>11</sub>H<sub>23</sub>)-Tyr-Leu-NH<sub>2</sub> (BP400)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,95	139,996	10,696	14,22
2	7,60	601,296	55,148	73,32
3	7,84	24,928	1,222	1,63
4	7,97	95,266	5,750	7,64
5	8,63	17,523	1,090	1,45
6	8,87	20,128	1,311	1,74
Total:		899,138	75,217	100,00

## HPLC of purified peptide ( $\lambda=220$ nm)






No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,60	518,077	42,421	100,00
Total:		518,077	42,421	100,00


## ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )








**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Lys(COC<sub>11</sub>H<sub>23</sub>)-Leu-NH<sub>2</sub> (BP401)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,15	281,402	27,972	12,86
2	7,39	69,176	5,638	2,59
3	7,71	955,947	132,927	61,10
4	8,07	251,104	27,182	12,49
5	8,46	36,744	2,231	1,03
6	9,11	103,107	10,872	5,00
7	10,42	100,065	10,747	4,94
Total:		1797,546	217,569	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)







No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,77	281,578	23,709	100,00
Total:		281,578	23,709	100,00

### ESI-MS ( $m/z$ )




# HRMS ( $m/z$ )






**Ac-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-Lys-Tyr-Lys(COC<sub>11</sub>H<sub>23</sub>)-NH<sub>2</sub> (BP402)**




HPLC of crude peptide ( $\lambda=220$  nm)




No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	6,81	566,169	49,463	11,20
2	7,24	1628,606	241,328	54,65
3	7,54	739,921	65,463	14,82
4	7,86	294,068	29,598	6,70
5	8,28	160,723	21,558	4,88
6	8,96	169,549	14,511	3,29
7	9,16	241,635	19,678	4,46
Total:		3800,670	441,600	100,00

### HPLC of purified peptide ( $\lambda=220$ nm)



No.	Ret.Time (detected) min	Height mAU	Area mAU*min	Rel.Area %
1	7,09	13,668	0,753	1,00
2	7,29	698,961	74,585	99,00
Total:		712,628	75,339	100,00

### ESI-MS ( $m/z$ )



# HRMS ( $m/z$ )

